Definitive Healthcare (NASDAQ:DH) Rating Increased to Strong-Buy at William Blair

William Blair upgraded shares of Definitive Healthcare (NASDAQ:DH) to a strong-buy rating in a research report released on Thursday,Zacks.com reports.

Other equities analysts have also issued reports about the company. Weiss Ratings restated a “sell (d-)” rating on shares of Definitive Healthcare in a research report on Wednesday, October 8th. Robert W. Baird set a $4.00 price objective on shares of Definitive Healthcare in a research note on Friday, August 8th. Finally, Stifel Nicolaus boosted their price objective on shares of Definitive Healthcare from $5.00 to $6.00 and gave the company a “buy” rating in a report on Friday, August 8th. One equities research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, four have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $4.28.

Definitive Healthcare Trading Up 10.6%

DH traded up $0.28 during trading on Thursday, reaching $2.93. 502,544 shares of the company’s stock were exchanged, compared to its average volume of 251,544. The company’s fifty day moving average price is $3.46 and its 200-day moving average price is $3.57. The firm has a market capitalization of $419.41 million, a PE ratio of -1.75 and a beta of 1.61. Definitive Healthcare has a fifty-two week low of $2.15 and a fifty-two week high of $5.68. The company has a debt-to-equity ratio of 0.39, a quick ratio of 1.65 and a current ratio of 1.65.

Definitive Healthcare (NASDAQ:DH) last posted its quarterly earnings results on Thursday, November 6th. The company reported $0.07 earnings per share for the quarter, beating analysts’ consensus estimates of $0.06 by $0.01. Definitive Healthcare had a positive return on equity of 3.14% and a negative net margin of 77.88%.The company had revenue of $60.05 million for the quarter, compared to the consensus estimate of $59.51 million. Definitive Healthcare has set its FY 2025 guidance at 0.230-0.240 EPS. Q4 2025 guidance at 0.050-0.060 EPS. As a group, equities analysts forecast that Definitive Healthcare will post 0.16 EPS for the current year.

Hedge Funds Weigh In On Definitive Healthcare

Hedge funds and other institutional investors have recently modified their holdings of the stock. Raymond James Financial Inc. bought a new stake in shares of Definitive Healthcare in the 2nd quarter worth about $32,000. Farther Finance Advisors LLC bought a new stake in shares of Definitive Healthcare during the second quarter valued at approximately $33,000. Savant Capital LLC purchased a new stake in shares of Definitive Healthcare in the 2nd quarter worth $45,000. Los Angeles Capital Management LLC bought a new position in Definitive Healthcare during the 2nd quarter worth about $51,000. Finally, Bayesian Capital Management LP purchased a new position in Definitive Healthcare during the second quarter valued at approximately $55,000. Institutional investors own 98.67% of the company’s stock.

About Definitive Healthcare

Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally. Its SaaS platform provides information on healthcare providers and their activities to help its customers from product development to go-to-market planning, and sales and marketing execution.